Literature DB >> 21839098

The involvement of FK506-binding protein 51 (FKBP5) in the behavioral and neuroendocrine effects of chronic social defeat stress.

Jakob Hartmann1, Klaus V Wagner, Claudia Liebl, Sebastian H Scharf, Xiao-Dong Wang, Miriam Wolf, Felix Hausch, Theo Rein, Ulrike Schmidt, Chadi Touma, Joyce Cheung-Flynn, Marc B Cox, David F Smith, Florian Holsboer, Marianne B Müller, Mathias V Schmidt.   

Abstract

Chronic stress is increasingly considered to be a main risk factor for the development of a variety of psychiatric diseases such as depression. This is further supported by an impaired negative feedback of the hypothalamic-pituitary-adrenal (HPA) axis, which has been observed in the majority of depressed patients. The effects of glucocorticoids, the main hormonal endpoint of the HPA axis, are mediated via the glucocorticoid receptor (GR) and the mineralocorticoid receptor. The FK506-binding protein 51 (FKBP5), a co-chaperone of the Hsp90 and component of the chaperone-receptor heterocomplex, has been shown to reduce ligand sensitivity of the GR. This study aimed to investigate the function of FKBP5 as a possible mediator of the stress response system and its potential role in the development of stress-related diseases. Therefore, we assessed whether mice lacking the gene encoding FKBP5 (51KO mice) were less vulnerable to the adverse effects of three weeks of chronic social defeat stress. Mice were subsequently analyzed with regards to physiological, neuroendocrine, behavioral and mRNA expression alterations. Our results show a less vulnerable phenotype of 51KO mice with respect to physiological and neuroendocrine parameters compared to wild-type animals. 51KO mice demonstrated lower adrenal weights and basal corticosterone levels, a diminished response to a novel acute stimulus and an enhanced recovery, as well as more active stress-coping behavior. These results suggest an enhanced negative glucocorticoid feedback within the HPA axis of 51KO mice, possibly modulated by an increased sensitivity of the GR. This article is part of a Special Issue entitled 'Anxiety and Depression'.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21839098     DOI: 10.1016/j.neuropharm.2011.07.041

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  80 in total

Review 1.  Animal models of stress vulnerability and resilience in translational research.

Authors:  Sebastian H Scharf; Mathias V Schmidt
Journal:  Curr Psychiatry Rep       Date:  2012-04       Impact factor: 5.285

Review 2.  Gene-Stress-Epigenetic Regulation of FKBP5: Clinical and Translational Implications.

Authors:  Anthony S Zannas; Tobias Wiechmann; Nils C Gassen; Elisabeth B Binder
Journal:  Neuropsychopharmacology       Date:  2015-08-13       Impact factor: 7.853

3.  FKBP51 inhibits GSK3β and augments the effects of distinct psychotropic medications.

Authors:  N C Gassen; J Hartmann; A S Zannas; A Kretzschmar; J Zschocke; G Maccarrone; K Hafner; A Zellner; L K Kollmannsberger; K V Wagner; D Mehta; S Kloiber; C W Turck; S Lucae; G P Chrousos; F Holsboer; E B Binder; M Ising; M V Schmidt; T Rein
Journal:  Mol Psychiatry       Date:  2015-04-07       Impact factor: 15.992

Review 4.  Stress-induced sex differences: adaptations mediated by the glucocorticoid receptor.

Authors:  Chase H Bourke; Constance S Harrell; Gretchen N Neigh
Journal:  Horm Behav       Date:  2012-03-03       Impact factor: 3.587

Review 5.  Are BDNF and glucocorticoid activities calibrated?

Authors:  F Jeanneteau; M V Chao
Journal:  Neuroscience       Date:  2012-09-26       Impact factor: 3.590

6.  Sex differences in stress-induced social withdrawal: independence from adult gonadal hormones and inhibition of female phenotype by corncob bedding.

Authors:  Brian C Trainor; Elizabeth Y Takahashi; Katharine L Campi; Stefani A Florez; Gian D Greenberg; Abigail Laman-Maharg; Sarah A Laredo; Veronica N Orr; Andrea L Silva; Michael Q Steinman
Journal:  Horm Behav       Date:  2013-02-04       Impact factor: 3.587

7.  FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder.

Authors:  Katarzyna A Ellsworth; Irene Moon; Bruce W Eckloff; Brooke L Fridley; Gregory D Jenkins; Anthony Batzler; Joanna M Biernacka; Ryan Abo; Abra Brisbin; Yuan Ji; Scott Hebbring; Eric D Wieben; David A Mrazek; Richard M Weinshilboum; Liewei Wang
Journal:  Pharmacogenet Genomics       Date:  2013-03       Impact factor: 2.089

Review 8.  The role of FKBP5 in mood disorders: action of FKBP5 on steroid hormone receptors leads to questions about its evolutionary importance.

Authors:  John C O'Leary; Bo Zhang; John Koren; Laura Blair; Chad A Dickey
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

9.  PACAP-deficient mice show attenuated corticosterone secretion and fail to develop depressive behavior during chronic social defeat stress.

Authors:  Michael L Lehmann; Tomris Mustafa; Adrian M Eiden; Miles Herkenham; Lee E Eiden
Journal:  Psychoneuroendocrinology       Date:  2012-10-11       Impact factor: 4.905

10.  FKBP51 Null Mice Are Resistant to Diet-Induced Obesity and the PPARγ Agonist Rosiglitazone.

Authors:  Lance A Stechschulte; Bin Qiu; Manya Warrier; Terry D Hinds; Man Zhang; Hao Gu; Yuxue Xu; Saja S Khuder; Lucia Russo; Sonia M Najjar; Beata Lecka-Czernik; Weidong Yong; Edwin R Sanchez
Journal:  Endocrinology       Date:  2016-07-21       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.